ADXS - Advaxis shares rise after receiving milestone payment under ADXS-HER2 licensing deal

Advaxis (ADXS) has received the second milestone payment related to its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, OS Therapies is responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma.OS Therapies recently completed a financing, triggering the second milestone payment.Under the agreement, Advaxis has the opportunity to receive additional clinical, regulatory, and sales-based milestone payments as well as royalties on future product sales.Additional details of the financial terms have not been disclosed.ADXS shares up 5.4% premarket.

For further details see:

Advaxis shares rise after receiving milestone payment under ADXS-HER2 licensing deal